Symdeko is developed by University of Alabama at Birmingham.

What development phase is Symdeko in?

Symdeko is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Symdeko

University of Alabama at Birmingham · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Symdeko
Also known as	Orkambi, Ivacaftor
Sponsor	University of Alabama at Birmingham
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Personalized Theratyping Trial (EARLY_PHASE1)
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations (PHASE4)
Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF). (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Symdeko CI brief — competitive landscape report
Symdeko updates RSS · CI watch RSS
University of Alabama at Birmingham portfolio CI